Penetration of foscarnet into cerebrospinal fluid of AIDS patients.
The diffusion of foscarnet into cerebrospinal fluid (CSF) was studied in 27 patients with AIDS. Foscarnet was administered intravenously at various dosages at 12-h intervals. Concentrations in plasma and CSF at the end of foscarnet infusion or 1, 3, 5, 6, and 12 h after infusion were determined by high-performance liquid chromatography. Thirty-seven samples were obtained. The median concentration of foscarnet in CSF was 80 mumol/liter (range, 0 to 500 mumol/liter). The CSF foscarnet concentration was greater than the 50% inhibitory concentration for human immunodeficiency virus type 1 and was equal to or greater than the 50% inhibitory concentration for cytomegalovirus in most cases. The penetration of foscarnet into CSF, as expressed by the ratio of the concentration in CSF to the simultaneous concentration in plasma, ranged from 0 to 3.4 (median, 0.27) and was highly correlated with the presence of cells within CSF and the length of foscarnet therapy. Good diffusion of foscarnet in CSF allows evaluation of this drug in central nervous system cytomegalovirus and human immunodeficiency virus infections in patients with AIDS.
Raffi
F
F
Hôpital Universitaire, Hotel-Dieu, Nantes, France.
Taburet
A M
AM
Ghaleh
B
B
Huart
A
A
Singlas
E
E
D000163:Acquired Immunodeficiency Syndrome / Q000134:cerebrospinal fluid*; D000328:Adult; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid; D008875:Middle Aged; D011485:Protein Binding
D017245:Foscarnet